DOI QR코드

DOI QR Code

In vitro hepatocyte inflammation by Ephedra sinica extracts

마황 추출물의 in vitro 간세포 염증반응 유도

  • Received : 2018.11.05
  • Accepted : 2018.12.06
  • Published : 2019.02.28

Abstract

In this study, the in vitro hepatotoxic mechanism of Ephedra sinica (ma-huang) was investigated by measuring the degree of cell death, secretion of cytokine, and fat accumulation by treating HepG2 cells with 70% ethanolic extracts of ma-huang. Cell death was observed at concentrations of around $5-100{\mu}g/mL$ by treatment with ma-huang extracts (p<0.05). The secretion of interleukin 8 (IL-8) and macrophage colony-stimulating factor (M-CSF), which are inflammatory cytokines, were significantly promoted at concentrations of around 0.05-100 and $0.5-100{\mu}g/mL$, respectively (p<0.05). In this experiment, it was shown that the extracts of ma-huang stimulate the secretion of inflammatory cytokines, such as IL-8 and M-CSF, and lead to fat accumulation in the hepatocytes, thereby causing inflammation of the hepatocytes. Hepatotoxicity was observed at around 10-500 times lower concentration than the concentration required to cause serious toxicity, such as cell death, suggesting that hepatic toxicity (hepatitis) may be induced at a low dose.

Keywords

Ephedra sinica (ma-huang);inflammation;interleukin-8;macrophage colony-stimulating factor;lipid accumulation

SPGHB5_2019_v51n1_24_f0001.png 이미지

Fig. 1. HepG2 cell viability by ma-huang extract.

SPGHB5_2019_v51n1_24_f0002.png 이미지

Fig. 2. LDH release of HepG2 cells by ma-huang extract.

SPGHB5_2019_v51n1_24_f0003.png 이미지

Fig. 3. IL-8 secretion of HepG2 cells by ma-huang extract.

SPGHB5_2019_v51n1_24_f0004.png 이미지

Fig. 4. M-CSF secretion of HepG2 cells by ma-huang extract.

SPGHB5_2019_v51n1_24_f0005.png 이미지

Fig. 5. Lipid accumulation of HepG2 cells by amiodarone (A) or ma-huang extract (B).

SPGHB5_2019_v51n1_24_f0006.png 이미지

Fig. 6. Confocal imaging of nile red binding in HepG2 cells after exposure to control (A), amiodarone (B) or ma-huang extract (C).

References

  1. Bajaj J1, Knox JF, Komorowski R, Saeian K. The irony of herbal hepatitis: Ma-Huang-induced hepatotoxicity associated with compound heterozygosity for hereditary hemochromatosis. Dig. Dis. Sci. 48: 1925-1928 (2003) https://doi.org/10.1023/A:1026105917735
  2. Bjornsson E. Drug-induced liver injury: Hy's rule revisited. Clin. Pharmacol. Ther. 79: 521-528 (2006) https://doi.org/10.1016/j.clpt.2006.02.012
  3. Browning JD, Horton JD. Molecular Mediators of Hepatic Steatosis and Liver Injury. J. Clin. Invest. 114: 147-152 (2004) https://doi.org/10.1172/JCI200422422
  4. Elewa H, Abd-Elmeneem M, Hashem AM, Alshehaby A. Study of interleukin 8 (IL8) serum level in patients with chronic liver disease due to hepatitis C virus (HCV) with and without hepatocellular carcinoma (HCC). Int. J. of Hepatol. 1: 9-17 (2010)
  5. Esterbauer H, Schaur RJ, Zollner H. Chemistry and Biochemistry of 4-Hydroxynonenal, Malonaldehyde and Related Aldehydes. Free Radic. Biol. Med. 11: 81-128 (1991) https://doi.org/10.1016/0891-5849(91)90192-6
  6. Estes JD, Stolpman D, Olyaei A, Corless CL, Ham JM, Schwartz JM, Orloff SL. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch. Surg. 138: 852-858 (2003) https://doi.org/10.1001/archsurg.138.8.852
  7. Gutierrez-Ruiz MC, Gomez Quiroz LE, Hernandez E, Bucio L, Souza V, Llorente L, Kershenobich D. Cytokine response and oxidative stress produced by ethanol, acetaldehyde and endotoxin treatment in HepG2 cells. Isr. Med. Assoc. J. 3: 131-136 (2001)
  8. Huang YS, Hwang SJ, Chan CY, Wu JC, Chao Y, Chang FY, Lee SD. Serum levels of cytokines in hepatitis C-related liver disease: a longitudinal study. Zhonghua Yi Xue Za Zhi 62: 327-333 (1999)
  9. Itoh Y, Okanoue T, Enjyo F, Sakamoto S, Ohmoto Y, Hirai Y, Kagawa K, Kashima K. Serum levels of macrophage colony stimulating factor (M-CSF) in Liver Disease. J. Hepatol. 21: 527-535 (1994) https://doi.org/10.1016/S0168-8278(94)80097-9
  10. Lee MK, Cheng BW, Che CT, Hsieh DP. Cytotoxicity assessment of Ma-huang (Ephedra) under different conditions of preparation. Toxicol. Sci. 56: 424-430 (2000) https://doi.org/10.1093/toxsci/56.2.424
  11. Nadir A, Agrawal S, King PD, Marshall JB. Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. Am. J. Gastroenterol. 91: 1436-1438 (1996)
  12. Shaw D. Toxicological risks of Chinese herbs. Planta. Med. 76: 2012-2018 (2010) https://doi.org/10.1055/s-0030-1250533
  13. Skoulidis F, Alexander GJ, Davies SE. Ma huang associated acute liver failure requiring liver transplantation. Eur. J. Gastroenterol. Hepatol. 17: 581-584 (2005) https://doi.org/10.1097/00042737-200505000-00017
  14. Stickel F, Patsenker E, Schuppan D. Herbal hepatotoxicity. J. Hepatol. 43: 901-910 (2005) https://doi.org/10.1016/j.jhep.2005.08.002
  15. Watkins PB, Seeff LB. Drug-induced liver injury: Summary of a single topic clinical research conference. Hepatology 43: 618-631 (2006) https://doi.org/10.1002/hep.21095
  16. Zhu Y, Li YG, Wang JB, Liu SH, Wang LF, Zhao YL, Bai YF, Wang ZX, Li JY, Xiao XH. Causes, Features, and Outcomes of Drug-Induced Liver Injury in 69 Children from China. Gut. Liver 9: 525-533 (2015) https://doi.org/10.5009/gnl14184
  17. Zimmermann HW, Seidler S, Gassler N, Nattermann J, Luedde T, Trautwein C, Tacke F. Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS One 6: e21381 (2011) https://doi.org/10.1371/journal.pone.0021381